Liver X receptors (LXRs) are cholesterol-sensing nuclear receptors that are not only key regulators of lipid metabolism and transport but also suppress inflammatory signaling in macrophages through a unique mechanism of transrepression. In this brief review, we focus on the regulatory actions of LXR primarily in macrophages responding to a proatherogenic environment. LXR potentially interferes with atherosclerosis by 2 different agonist-dependent signaling pathways. The first is through promoting reverse cholesterol transport by directly activating genes of cellular cholesterol export. The second is through a general inhibitory action on proinflammatory genes where sumo-modified and agonist-bound LXR recruits negative coregulatory proteins to nuclear factor B at immune response gene promoters through protein-protein interactions. The antiinflammatory actions of LXR may be a direct response to the proinflammatory actions recently proposed for cholesterol on inflammasome activity in the vessel wall. (Circ Res. 2011;108:996-1001.) 
many assay systems. 7 Thus, there is likely a significant level of redundancy at the molecular level suggesting that distinct functional roles may mostly be attributable to differences in patterns and levels of expression of the receptors than any inherent differences between the receptor proteins themselves. However, a recent report suggests that the 2 LXRs may play slightly different roles in regulating gene expression and atherogenesis. 8 
LXR␣ in Cholesterol Metabolism
An important physiological role for LXR␣ in cholesterol metabolism was revealed when normal-appearing chow-fed LXR␣ Ϫ/Ϫ mice were challenged with a high-cholesterol diet. 9 These mice developed severe hepatic pathology attributable to toxic accumulation of cholesterol from a failure in the feed-forward mechanism that normally increases bile acid production from cholesterol. 9 Oxysterols were identified as endogenous LXR agonists, 3 and over the last several years, models for how LXR functions in a signaling pathway involving hepatic/ intestinal communication and several nuclear receptors that together modulate flux through the cholesterol/bile acid synthetic pathway have been developed. 10, 11 The mechanism assumes that elevated hepatic cholesterol levels are sensed by LXR, which then activates expression of the gene encoding cholesterol 7␣-hydroxylase (CYP7A1), the rate-limiting enzyme in the neutral bile acid synthetic pathway in the mouse liver. This provides a metabolite based feed-forward mechanism that delivers cholesterol for conversion into bile acids to prevent cholesterol overaccumulation. 12, 13 CYP7A1 is a regulatory hub and is also subject to feedback regulation by bile acids, and it also integrates physiological input from several other signaling pathways that influence whole body metabolism. 11 Interestingly, the feed-forward mechanism for CYP7A1 regulation by LXR is not conserved in humans, 14 which emphasizes the limitation of rodent studies in this system as predictors of human metabolism.
Comparing the effects of treating wild-type (Wt) and LXR Ϫ/Ϫ mice with synthetic LXR agonists has revealed major insights into LXR action in vivo. Lipid profiling showed that LXR agonist treatment results in severe hypertriglyceridemia and hepatic steatosis in Wt but not LXR Ϫ/Ϫ mice. 6, 15 When combined with additional animal studies and complementary cell culture and in vitro mechanistic analyses, a fundamental role for LXR␣ in activating hepatic lipogenesis was documented. In this mechanism, LXR acts indirectly by binding to the promoter and activating expression of the SREBP-1c (sterol regulatory element binding protein 1c) gene. 6, 15 LXR also directly activates expression of the gene encoding ChREBP (carbohydrate response-element binding protein), which is the other major transcriptional activator of lipogenesis in the liver. 16 Thus, LXR increases levels of SREBP-1c and ChREBP proteins, and together they directly activate most, if not all, of the genes required for hepatic lipogenesis and triglyceride secretion.
Additional studies demonstrated that LXR agonist still activated several lipogenic genes in the liver of SREBP-1c knockout mice, 17 and LXR was also shown to directly activate key lipogenic genes directly. 7 Why there would be a need for LXR to activate lipogenic genes directly, as well as indirectly, through SREBP-1c is not entirely clear. A subset of oxysterols bind the endoplasmic reticulum resident Insig protein and could inhibit the proteolytic maturation of SREBP-1. 18 This would limit the effectiveness of the SREBP-1c pathway, and direct activation by LXR would be required to stimulate lipogenesis.
In contrast to CYP7A1 regulation, this pathway appears to be conserved in humans. The functional significance of why a cholesterol sensor should increase hepatic fatty acid biosynthesis is not totally clear and does not appear to occur in other normal cells where LXR␣ is expressed. However, a reasonable scenario suggests that activation of hepatic lipogenesis would ensure adequate fatty acids for conversion of the otherwise toxic (and possibly proinflammatory) free sterol to sterol-ester.
LXRs and Atherosclerosis
Even though activation of LXR signaling can have adverse effects on serum and hepatic lipids in mice, 7 studies have demonstrated that chronic administration of LXR agonists dramatically decrease lesion formation in both low-density lipoprotein receptor (LDLR) and apolipoprotein E knockoutmediated atherosclerosis mouse models. 19 Because LXRs are expressed in several tissues and LXR agonist administration results in elevated serum and hepatic lipids, as well as decreased cholesterol absorption, simple comparative studies in Wt versus LXR knockout mice could not directly address the importance of individual tissues in the antiatherogenic response. To address this issue, LXR knockout and agonistfeeding studies have been evaluated, and when taken in total, they suggest that LXR expressed in macrophages is key to the reduction in atherosclerosis. 20 The most direct experiments demonstrating this come from combinatorial transplantation studies using bone marrow from Wt or LXR␣/␤ double knockout mice to repopulate bone marrow from irradiated LDLR and apolipoprotein E knockout mice. 21, 22 These studies indicate that disease protection is provided mainly by LXR activity in bone marrow-derived cell lineages and also provide strong evidence that the effects are at least somewhat independent of LXR action in other tissues of the body, most 
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notably, liver and intestine. However, some studies have demonstrated that whereas bone marrow-derived LXR accounts for a majority of the lesion-reducing effects through LXR agonist treatment, there was a greater reduction when LXR␣ was also expressed in other tissues. 8 Macrophages develop from the bone marrow and are known to play key roles in lipid metabolism and atherosclerosis. 23 LXR agonists increase reverse cholesterol transport (RCT) from macrophages by increasing expression of macrophage apolipoprotein E and cholesterol efflux transporters ABCA1 and ABCG1 (ATP-binding cassette, subfamily A, member 1 and ATP-binding cassette, subfamily G, member 1, respectively). This is likely an important part of the mechanism for LXR-dependent protection from atherosclerosis because these effects are not observed in agonist-treated LXR knockout mice or their isolated macrophages. 22 Excess accumulation of cholesterol within macrophages at sites of atherosclerotic lesions converts them into foam cells and accounts for the major fraction of lesion deposited cholesterol. 24 Thus, by stimulating RCT, LXR reduces foam cell formation and lesion cholesterol content directly.
Cholesterol crystals within macrophages have been recently proposed as an initiator of a proinflammatory signaling response at developing atherosclerotic lesions, 25, 26 and it is well documented that inflammation and inflammatory signaling plays a significant role in the pathology of atherosclerosis. 27 Similar to the mechanism whereby uric acid crystals increase inflammation associated with gout, 28 (Figure) . Caspase-1 then converts pro-interleukin-1␤ and prointerleukin-18 to their active cytokine forms and stimulates an NF-B-dependent proinflammatory cascade. These observations suggest that excess intracellular cholesterol may also contribute to severity of atherosclerosis by directly promoting inflammation. Interestingly, LXR not only increases expression of genes for RCT in macrophages but also independently attenuates the inflammatory response. 29 This suggests LXR agonists probably amplify a natural inhibitory response to intracellular cholesterol. In this unusual role, LXR is not recruited to LXR response elements within proinflammatory gene promoters but is recruited through a "transrepression" mechanism where sumo-modified and agonist-bound LXR forms a complex with transcriptional corepressors N-CoR (nuclear receptor corepressor) and/or SMRT (silencing mediator for retinoid and thyroid hormone receptors). 30, 31 The protein complex interacts with NF-B, which targets the entire complex to promoters through NF-B binding sites. As a result, the recruitment of the corepressor activities dampens the NF-B activation response at inflammatory gene promoters (Figure) . It is intriguing that intracellular sterols might initiate an inflammatory response, as well as activate LXR. Thus, the antiinflammatory effect of LXR action may have evolved as a response to the proinflammatory actions of intracellular sterols.
Figure.
Model for the action of intracellular cholesterol as a danger-associated molecular pattern (DAMP). Free cholesterol initiates an inflammatory response but could also result in conversion to LXR agonist, which would stimulate a trans-repressive antiinflammatory response (Illustration credit: Cosmocyte/Ben Smith).
Macrophages also initiate an inflammatory response on bacterial infection, and it is well documented that infection by
Chlamydia pneumoniae is associated with enhanced foam cell formation and atherosclerosis development, which are reduced in animal models that lack toll-like receptor signaling pathway components. 32, 33 This suggested that an inflammatory response to infection by this pathogen contributes to its effects on atherosclerosis. Naiki et al 33 also showed that LXR agonist treatment reduced foam cell formation enhanced by C pneumoniae infection as well. Thus, it is likely that LXR has a general role in limiting inflammation linked to atherosclerosis and probably other diseases, and LXR agonists could be therapeutic for combating inflammation regardless of the initiating insult.
Thus, LXR interferes with the pathology of atherosclerosis by 2 complementary agonist-dependent signaling pathways in macrophages. One is through directly activating genes to promote RCT and limit cholesterol deposition, and the other is through inhibiting proinflammatory gene expression, which reduces lesion-associated inflammation.
In contrast to the well-studied role of LXR signaling in macrophages, how LXR action in other cells that may directly influence atherosclerosis such as endothelial and smooth muscle cells (SMCs) is less well studied. Smooth muscle cells play an essential role in blood vessel integrity and rhythmic contracture. SMCs also influence atherosclerosis progression by protecting mature plaques from rupture. 34 LXR␤ is expressed in vascular SMCs, and LXR agonist treatment prevents neointima formation following vascular injury, which is consistent with a role in decreased SMC proliferation as well. 35 There is also evidence that genes involved in RCT are also upregulated in smooth muscle, so they may help limit cholesterol deposition during plaque development as well. 36 LXR target gene expression in endothelial cells is increased when they are exposed to high laminar flow in culture; conditions that mimic normal high volume arterial blood flow. Whereas LXR expression is significantly lower in vessel regions subjected to turbulent blood flow such as in the aortic arch. 37 These results suggest that in endothelial cells, LXR may respond to changes in blood flow to possibly influence RCT and reduce inflammation similar to LXR activity in macrophages. This would also have beneficial effects in limiting atherogenesis.
LXRs As Regulators of the Innate Immune Response
The role of LXR signaling in inflammation suggested it might also be a more general modulator of the innate immune system responses to pathogen engagement. Transcription profiling of LXR-null and Wt mice subjected to bacterial challenge by Listeria monocytogenes identified AIM (apoptotic inhibitor of macrophages) (also known as SP␣ [scavenger receptor cysteine-rich repeat protein] or API6 [apoptosis inhibitor 6]) as a target of LXR signaling. 38 Mechanistic studies documented there is a functional LXR binding site located in the AIM gene distal 5Ј flanking region. AIM functions to prevent cells from undergoing apoptosis 39 and increases survival of infected cells after bacterial challenge. 38 It was also demonstrated that SP␣ increased macrophage cell survival and decreased bacterial load after infection by L monocytogenes and other pathogenic bacteria in an LXRdependent manner. 38 Interestingly, in a follow-up study using AIM-null/LDLR-null double knockout mice, expression of AIM was shown to contribute to macrophage survival in the atherosclerotic plaque, which may also contribute to the protective effects of LXR signaling that limit atherosclerosis. 40 Paradoxically, AIM knockout mice were protected from developing atherosclerosis presumably because of increased apoptosis of macrophages during the early stages of plaque development. Thus, the mechanisms for LXR signaling in development of atherosclerosis may be complex, with some aspects being beneficial and others complicating the disease process. LXR-null macrophages have also been used to demonstrate that LXR plays a key role in phagocytosis of apoptotic thymocytes, a role that couples innate with adaptive immune responses 41 and would be predicted to be beneficial in limiting plaque deposition in advanced atherosclerotic lesions. 42 The Mer receptor tyrosine kinase was identified as a candidate LXR gene target involved in this response. Mer is one of a group of molecules that facilitate phagocytosis by interacting with cell surface proteins on apoptotic cells. A-Gonzalez et al 41 showed that LXR binds and induces Mer expression in a feed-forward mechanism to enhance apoptotic T-cell clearance and a deficiency of either LXR or Mer reduced this effect. Interestingly, LXR and Mer are specifically required for the phagocytosis of apoptotic cells and not other phagocytic responses that occur in response to other initiating events. The phagocytosis of apoptotic thymocytes is also known to be associated with the inhibition of inflammatory signaling. This response was also reduced in LXR null macrophages suggesting that the suppression of inflammatory signaling during phagocytosis of apoptotic cells could be an additional physiological context for the transrepressive effects of LXR on inflammation.
Translational Perspectives
Studies in mice using LXR knockout animals and synthetic LXR agonist treatment have provided a wealth of information on the roles that LXRs play in coordinating lipid metabolism with other physiological processes. This has established LXR as a key factor linking mammalian lipid metabolism with the innate immune response.
How well the results from mouse studies will be predictive of potentially targeting LXR pathways in humans for therapy is not clear. The mouse models of atherosclerosis are limited and are not useful models for more advanced human atherosclerotic lesions. There is evidence that LXRs not only prevent but also may reverse plaque development so that targeting early lesions in humans with LXR intervention may be more likely to be effective. Many of the LXR targets in the mouse are also LXR targets in humans and play roles in RCT, which would prove beneficial for LXR based therapy. However, other LXR target genes such as AIM appear to play a more complicated role in atherosclerosis by protecting macrophages from apoptosis at lesion sites. This may be advantageous later in plaque development but paradoxically AIM knockout mice have reduced lesion development. This is likely because when AIM knockout macrophages are recruited to early lesion sites, they undergo apoptosis and fail to nucleate the growth of a developing plaque. 40 Key molecular targets of LXR are also different in humans versus mice. As mentioned earlier, CYP7A1 is regulated by LXR in mice but not humans. The small heterodimer partner (SHP) nuclear receptor contains a dimerization domain but lacks the canonical zinc-finger DNA binding domain. SHP dimerizes with other nuclear receptors but inhibits their activity to help mediate bile acid feedback regulation. SHP is an LXR target in humans but not in mice, 14 and the human LXR␣ gene is autoregulated in humans but not in mice. 43 There are also probably additional examples of species differences in LXR action as well. Thus, because of significant molecular genetic differences between humans and mice and the limitations of existing mouse models available for comparative atherosclerosis studies, it is challenging to predict how best to therapeutically target the LXR pathway for treatment in humans.
Finally, because of its role in stimulating hepatic lipogenesis, LXR agonist treatment results in significant hepatic steatosis in mice. 7 This could significantly contribute to metabolic syndrome abnormalities, as well as progress to steatohepatitis with severe specific liver damage. 44 Thus, despite the positive effects on atherosclerosis in mouse models, targeting LXR for therapeutic purposes in humans must overcome this significant obstacle. With this in mind, recent studies suggest that at least some synthetic LXR agonists may retain the beneficial effects on atherosclerosis without the effects on liver triglyceride accumulation. 45 There is also more recent evidence that selective LXR agonists may also have similar effects in nonhuman primates. 46 Thus, there is promising evidence that it will be possible to produce selective LXR modulators that retain the beneficial effects on atherosclerosis without the complicating effect on liver triglyceride metabolism.
